M. Parniak

发表

First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G.

N. Krogan, C. Schiffer, R. Harris, 2012, ACS chemical biology.

Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.

S. Sarafianos, S. Hughes, E. Arnold, 2009, Journal of molecular biology.

3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations.

S. Sarafianos, F. Liu, E. Nagy, 2016, Journal of medicinal chemistry.

Nanocrystal Formulation Improves Vaginal Delivery of CSIC for HIV Prevention

Michael A. Parniak, Sravan Kumar Patel, Byron Ballou, 2019, AAPS PharmSciTech.

Preformulation and Vaginal Film Formulation Development of Microbicide Drug Candidate CSIC for HIV Prevention

Phalguni Gupta, L. Rohan, M. Parniak, 2017, Journal of Pharmaceutical Innovation.

Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH)

P. Waters, M. Parniak, C. Scriver, 1998, Human mutation.

Missense mutations in the phenylalanine hydroxylase gene (PAH) can cause accelerated proteolytic turnover of PAH enzyme: A mechanism underlying phenylketonuria

P. Waters, M. Parniak, C. Scriver, 1999, Journal of Inherited Metabolic Disease.

Homomeric and heteromeric interactions between wild-type and mutant phenylalanine hydroxylase subunits: evaluation of two-hybrid approaches for functional analysis of mutations causing hyperphenylalaninemia.

P. Waters, M. Parniak, C. Scriver, 2001, Molecular genetics and metabolism.

Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype.

P. Waters, M. Parniak, C. Scriver, 2000, Molecular Genetics and Metabolism.

ORGANIZATION OF THE CATALYTIC AND REGULATORY SITES OF RAT LIVER PHENYLALANINE HYDROXYLASE

M. Parniak, 1987 .

Comparative analysis of phenylalanine hydroxylase A104D mutant, associated with variant phenylketonuria, and wild-type enzyme.

P. Knappskog, M. Parniak, C. Scriver, 1997, Biochemical Society transactions.

In vitro expression analysis of mutations in phenylalanine hydroxylase: Linking genotype to phenotype and structure to function

P. Waters, M. Parniak, C. Scriver, 1998, Human mutation.

Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.

N. Sluis-Cremer, M. Parniak, D. Arion, 2004, The international journal of biochemistry & cell biology.

Development of Human Immunodeficiency Virus Type 1 Resistance to 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains

S. Sarafianos, H. Mitsuya, E. Nagy, 2021, Antimicrobial agents and chemotherapy.

Development of Resistance to 4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine (EFdA) by WT and Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Virus Type 1

S. Sarafianos, H. Mitsuya, E. Nagy, 2020, bioRxiv.

Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1

M. Wainberg, H. Salomón, Q. Gao, 2005, Archives of Virology.

Primer Unblocking and Rescue of DNA Synthesis by Azidothymidine (AZT)-resistant HIV-1 Reverse Transcriptase

C. Ehresmann, B. Ehresmann, R. Marquet, 2002, The Journal of Biological Chemistry.

Inhibitors of HIV- I reverse transcriptase

N. Sluis-Cremer, M. Parniak, 2000 .

Mechanism by Which Phosphonoformic Acid Resistance Mutations Restore 3′-Azido-3′-deoxythymidine (AZT) Sensitivity to AZT-resistant HIV-1 Reverse Transcriptase*

N. Sluis-Cremer, M. Parniak, D. Arion, 2000, The Journal of Biological Chemistry.

HIV resistance to zidovudine: the role of pyrophosphorolysis.

M. Parniak, D. Arion, 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

The Thiocarboxanilide Nonnucleoside Inhibitor UC781 Restores Antiviral Activity of 3′-Azido-3′-Deoxythymidine (AZT) against AZT-Resistant Human Immunodeficiency Virus Type 1

M. Wainberg, M. Parniak, G. Borkow, 1999, Antimicrobial Agents and Chemotherapy.

Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively

M. Wainberg, M. Parniak, Y. Quan, 1996, Journal of virology.

Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs

M. Wainberg, Q. Gao, M. Tremblay, 1991, Antimicrobial Agents and Chemotherapy.

Clinical significance and characterization of AZT-resistant strains of HIV-1.

J. Montaner, M. Wainberg, Q. Gao, 1991, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.

J. Balzarini, M. Camarasa, N. Sluis-Cremer, 2000, Biochemistry.

Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection.

E. Kool, S. Garforth, M. Parniak, 2007, Journal of molecular biology.

Stimulation of Interferon $ Gene Transcrition in Vitro by Purified NF-icB and a Novel TH Protein

J. Hiscott, J. Lacoste, M. Parniak, 1991 .

Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1.

M. Wainberg, I. Lowy, J. Mak, 1997, Journal of molecular biology.

Structure–activity relationships in HIV‐1 reverse transcriptase revealed by radiation target analysis

N. Sluis-Cremer, E. Kempner, M. Parniak, 2003, Protein science : a publication of the Protein Society.

The role of phenylalanine in structure-function relationships of phenylalanine hydroxylase revealed by radiation target analysis.

S. Kaufman, E. Kempner, M. Parniak, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Effect of tRNA on the Maturation of HIV-1 Reverse Transcriptase.

S. Sarafianos, R. Ishima, M. Parniak, 2018, Journal of molecular biology.

Rat liver phenylalanine hydroxylase. Activation by sulfhydryl modification.

S. Kaufman, M. Parniak, 1981, The Journal of biological chemistry.

Effects of Substitutions at the 4′ and 2 Positions on the Bioactivity of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine

S. Sarafianos, S. Hughes, H. Mitsuya, 2013, Antimicrobial Agents and Chemotherapy.

Structural integrity of the ribonuclease H domain in HIV‐1 reverse transcriptase

Justin Spiriti, D. Zuckerman, R. Ishima, 2015, Proteins.

Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.

M. Parniak, Nataliya S. Myshakina, Zhengqiang Wang, 2013, Journal of medicinal chemistry.

Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)

S. Sarafianos, H. Mitsuya, E. Kodama, 2016, Proceedings of the National Academy of Sciences.

Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase.

Andrew D. Huber, S. Sarafianos, M. Parniak, 2017, European journal of medicinal chemistry.

Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission

S. Sarafianos, Yuan-Ping Shi, Minlu Hu, 2015, Pharmaceutical Research.

Time-dependent alterations in the pathway of glucose incorporation into glycogen in primary cultures of rat hepatocytes following glucose starvation.

M. Parniak, N. Kalant, 1988, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication

M. Wainberg, E. Arts, J. Mak, 1994, Journal of virology.

Effects of copper and histidine on oxidative modification of low density lipoprotein and its subsequent binding to collagen.

M. Parniak, N. Kalant, S. McCormick, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Radiation target analysis indicates that phenylalanine hydroxylase in rat liver extracts is a functional monomer

S. Kaufman, E. Kempner, M. Parniak, 1999, FEBS letters.

A capillary electrophoretic assay for ribonuclease H activity.

S. L. Le Grice, J. Mcmahon, R. Crouch, 2004, Analytical biochemistry.

A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity.

S. L. Le Grice, M. Parniak, J. Beutler, 2003, Analytical biochemistry.

Isolation and fractionation of retroviral tRNAs.

L. Kleiman, M. Parniak, M. Jiang, 1992, Journal of virological methods.

Design, Synthesis, Biochemical, and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxylisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities

S. Sarafianos, E. Nagy, M. Parniak, 2014, Journal of medicinal chemistry.

Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNase H domain of HIV-1 reverse transcriptase and structure-activity analysis of inhibitor analogs.

E. Arnold, W. Ho, M. Parniak, 2014, Journal of molecular biology.

Preclinical Safety Assessments of UC781 Anti-Human Immunodeficiency Virus Topical Microbicide Formulations

S. Hillier, L. Rohan, M. Parniak, 2007, Antimicrobial Agents and Chemotherapy.

Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission

C. Dezzutti, L. Rohan, M. Parniak, 2011, Drug Delivery and Translational Research.

Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1

M. Wainberg, J. Darlix, L. Kleiman, 1997, Journal of virology.

The interaction of aromatic amino acids with rat liver phenylalanine hydroxylase.

S. Kaufman, R. Phillips, M. Parniak, 1984, The Journal of biological chemistry.

Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

S. Sarafianos, H. Mitsuya, K. Singh, 2012, Cellular and molecular biology.

The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC.

S. Hughes, M. Parniak, C. Davis, 2011, Virology.

The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site

S. Sarafianos, M. Parniak, M. Abram, 2010, Retrovirology.

HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.

Jennifer L. Knight, A. D. Clark, R. Levy, 2006, ACS chemical biology.

Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.

M. Wainberg, M. Parniak, G. Borkow, 1995, Biochemistry.

Compartmentation of glucose 6-phosphate in hepatocytes.

M. Parniak, N. Kalant, M. Lemieux, 1987, The Biochemical journal.

The 3′-Azido Group Is Not the Primary Determinant of 3′-Azido-3′-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1*

J. Mellors, R. Schinazi, N. Sluis-Cremer, 2005, Journal of Biological Chemistry.

Sensitivity and Resistance to (+)-Calanolide a of Wild-Type and Mutated Forms of HIV-1 Reverse Transcriptase

M. Wainberg, M. Parniak, R. Buckheit, 1998, Antiviral therapy.

Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT‐Resistant Variants of HIV‐1

J. Montaner, M. Wainberg, J. Ruedy, 1990, Annals of the New York Academy of Sciences.

Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.

M. Parniak, G. Dmitrienko, S. Mithani, 1995, Biochemistry.

Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA

J. Garcia, M. Parniak, P. Ho, 2016, PloS one.

Biopterin metabolism and phenylalanine hydroxylase activity during early liver regeneration.

S. Kaufman, M. Parniak, H. Wilgus, 1982, Biochemical and biophysical research communications.

In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NNRTI-Resistant Human Immunodeficiency Virus Type 1

M. Parniak, M. Hossain, 2006, Journal of Virology.

Clinically Used Antiretroviral Drugs -Deoxyadenosine with ' -Ethynyl-2-Fluoro-2 ' Evaluation of Combinations of 4

H. Mitsuya, S. Oka, E. Kodama, 2014 .

Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs

S. Sarafianos, H. Mitsuya, S. Oka, 2013, Antimicrobial Agents and Chemotherapy.

Inhibition of carboxypeptidase a by N-(4-t-Butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone

M. Parniak, G. Dmitrienko, Christopher M. Lanthier, 1997 .

Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones

S. L. Le Grice, J. Mcmahon, I. Gorshkova, 2005, Nucleic acids research.

Synthesis and biophysical properties of arabinonucleic acids (ANA): circular dichroic spectra, melting temperatures, and ribonuclease H susceptibility of ANA.RNA hybrid duplexes.

A. Noronha, C. Wilds, C. Lok, 2000, Biochemistry.

HYBRIDS OF RNA AND ARABINONUCLEIC ACIDS (ANA AND 2'F-ANA) ARE SUBSTRATES OF RIBONUCLEASE H

I. Brukner, A. Noronha, C. Wilds, 1998 .

Chemical Barriers to Human Immunodeficiency Virus Type 1 ( HIV-1 ) Infection : Retrovirucidal Activity of UC 781 , a Thiocarboxanilide Nonnucleoside Inhibitor of HIV-1 Reverse Transcriptase

M. Wainberg, M. Parniak, J. Barnard, 1996 .

The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes

S. Sarafianos, R. Aurora, J. Tavis, 2013, PLoS pathogens.

Synthesis and properties of 2'-deoxy-2',4'-difluoroarabinose-modified nucleic acids.

G. Portella, M. Orozco, Carlos González, 2015, The Journal of organic chemistry.

Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2'F-ANA constructs containing acyclic nucleotide inserts.

A. Galarneau, M. Damha, M. Parniak, 2003, Journal of the American Chemical Society.

Oligonucleotides comprised of alternating 2'-deoxy-2'-fluoro-beta-D-arabinonucleosides and D-2'-deoxyribonucleosides (2'F-ANA/DNA 'altimers') induce efficient RNA cleavage mediated by RNase H.

A. Galarneau, M. Damha, M. Parniak, 2002, Bioorganic & medicinal chemistry letters.

Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity

S. Sarafianos, R. Ishima, M. Parniak, 2012, Biology.

Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.

Andrew D. Huber, S. Sarafianos, M. Parniak, 2017, Journal of medicinal chemistry.

Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.

M. Parniak, J. Barnard, G. Borkow, 1997, Biochemistry.

Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase.

M. Wainberg, E. Nagy, M. Parniak, 1996, Protein expression and purification.

Mutational analysis of Lys65 of HIV-1 reverse transcriptase.

N. Sluis-Cremer, M. Parniak, D. Arion, 2000, The Biochemical journal.

The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.

M. Wainberg, E. Arts, M. Parniak, 1994, The Journal of biological chemistry.

Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.

M. Wainberg, E. Arts, L. Kleiman, 1994, The Journal of biological chemistry.

Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine In Vitro and In Vivo

S. Sarafianos, H. Mitsuya, M. Parniak, 2012, Antimicrobial Agents and Chemotherapy.

Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris.

M. Wainberg, Xiaojian Yao, M. Parniak, 1992, Virology.

Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.

D. Hazuda, J. Krueger, M. Parniak, 2005, Biochemistry.

Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.

E. Oldfield, Kilannin Krysiak, Yongcheng Song, 2008, Bioorganic & medicinal chemistry.

Characterization of Cyclodextrin Inclusion Complexes of the Anti-HIV Non-Nucleoside Reverse Transcriptase Inhibitor UC781

Haitao Yang, S. Hillier, L. Rohan, 2008, The AAPS Journal.

A thermodynamic study of the cyclodextrin-UC781 inclusion complex using a HPLC method

Haitao Yang, S. Hillier, L. Rohan, 2012, Journal of Inclusion Phenomena and Macrocyclic Chemistry.

Determination of the phosphate content of purified proteins.

S. Kaufman, M. Parniak, H. Hasegawa, 1982, Analytical biochemistry.

Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase

M. Wainberg, H. Salomón, W. C. Drosopoulos, 1996, Science.

Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors.

N. Sluis-Cremer, M. Parniak, D. Arion, 2002, Molecular pharmacology.

Inhibitors of HIV-1 reverse transcriptase.

N. Sluis-Cremer, M. Parniak, 2000, Advances in pharmacology.

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

M A Wainberg, M. Wainberg, H. Salomón, 1994, Antimicrobial Agents and Chemotherapy.

Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.

Andrew D. Huber, S. Sarafianos, M. Parniak, 2019, European journal of medicinal chemistry.

6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.

Andrew D. Huber, S. Sarafianos, Jiashu Xie, 2018, European journal of medicinal chemistry.

6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H.

Andrew D. Huber, S. Sarafianos, M. Parniak, 2018, European journal of medicinal chemistry.

A 2-Hydroxyisoquinoline-1,3-Dione Active-Site RNase H Inhibitor Binds in Multiple Modes to HIV-1 Reverse Transcriptase

Andrew D. Huber, Skyler T. Kramer, S. Sarafianos, 2017, Antimicrobial Agents and Chemotherapy.

3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H

Andrew D. Huber, S. Sarafianos, H. Mitsuya, 2017, Antimicrobial Agents and Chemotherapy.

Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H.

S. Sarafianos, F. Liu, E. Nagy, 2016, Journal of medicinal chemistry.

Structure-function relationships of phenylalanine hydroxylase revealed by radiation target analysis.

S. Kaufman, E. Kempner, M. Parniak, 1996, Archives of Biochemistry and Biophysics.

Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase

S. Sarafianos, M. Parniak, B. Marchand, 2012, Antimicrobial Agents and Chemotherapy.

Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention

S. Sarafianos, H. Mitsuya, L. Rohan, 2014, Drug development and industrial pharmacy.

In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers.

S. Sarafianos, P. Empey, L. Rohan, 2014, European journal of pharmacology.

Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides.

Phalguni Gupta, D. Ratner, S. Hillier, 2006, AIDS research and human retroviruses.

Alterations in cell tetrahydrobiopterin levels may regulate queuine hypomodification of tRNA during differentiation of murine erythroleukemia cells.

L. Kleiman, M. Parniak, S. Marx, 1991, Experimental cell research.

On the phosphate content of rat liver phenylalanine hydroxylase purified by hydrophobic chromatography.

S. Kaufman, M. Parniak, H. Wilgus, 1981, Biochemical and biophysical research communications.

The utility of self-emulsifying oil formulation to improve the poor solubility of the anti HIV drug CSIC

L. Rohan, C. Esimone, M. Parniak, 2013, AIDS Research and Therapy.

Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque

S. Sarafianos, M. Parniak, M. Murphey-Corb, 2015, Antimicrobial Agents and Chemotherapy.

The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

S. Sarafianos, H. Mitsuya, K. Singh, 2011, Cellular and molecular biology.

Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor*

S. Sarafianos, M. Matsuoka, H. Mitsuya, 2009, The Journal of Biological Chemistry.

Nucleotide Sugar Pucker Preference Mitigates Excision by HIV-1 RT.

G. Deleavey, M. Damha, M. Parniak, 2015, ACS chemical biology.

Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)

N. Sluis-Cremer, M. Parniak, D. Arion, 2000, Cellular and Molecular Life Sciences CMLS.

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA

Andrew D. Huber, S. Sarafianos, H. Mitsuya, 2013, Retrovirology.

4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms*

Andrew D. Huber, S. Sarafianos, H. Mitsuya, 2014, The Journal of Biological Chemistry.

Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.

M. Wainberg, C. Liang, M. Parniak, 1998, Journal of molecular biology.

Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.

M. Wainberg, E. Arts, M. Parniak, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1

R. Esnouf, E. De Clercq, A. Vandamme, 1997, Journal of virology.

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

M. Wainberg, Q. Gao, C. Boucher, 1993, Antimicrobial Agents and Chemotherapy.

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.

M. Parniak, G. Borkow, D. Arion, 1998, Biochemistry.

Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT.

R. Esnouf, E. De Clercq, J. Balzarini, 2001, Virology.

Preclinical studies on thiocarboxanilide UC‐781 as a virucidal agent

L. van Damme, E. De Clercq, L. Naesens, 1998, AIDS.

A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.

R. Esnouf, E. De Clercq, A. Vandamme, 1998, The Journal of general virology.

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

M A Wainberg, M. Wainberg, Q. Gao, 1992, Journal of virology.

Inhibitory potency of R-region specific antisense oligonucleotides against in vitro DNA polymerization and template-switching reactions catalysed by HIV-1 reverse transcriptase.

A. Noronha, M. Damha, M. Parniak, 1997, The international journal of biochemistry & cell biology.

Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1.

M. Wainberg, S. Wise, L. Kleiman, 2000, Journal of molecular biology.

Utilization of a Deoxynucleoside Diphosphate Substrate by HIV Reverse Transcriptase

S. Garforth, M. Parniak, V. Prasad, 2008, PloS one.

J. Balzarini, M. Camarasa, N. Sluis-Cremer, 2000, Biochemistry.

The Safety, Persistence, and Acceptability of an Antiretroviral Microbicide Candidate UC781

L. Meyn, K. Bunge, S. Hillier, 2012, Journal of acquired immune deficiency syndromes.

The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.

M. Parniak, J. Barnard, G. Borkow, 1997, Biochemistry.

The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis

M. Wainberg, M. Parniak, M. Götte, 2000, Journal of Virology.

Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC‐resistant HIV‐1 reverse transcriptase

Michael A. Parniak, Gadi Borkow, M. Wainberg, 1996, AIDS.

3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase.

S. Sarafianos, E. Arnold, M. Parniak, 2007, Biochemistry.

Generation and characterization of murine monoclonal antibodies reactive against N‐terminal and other regions of HIV‐1 reverse transcriptase

M. Wainberg, Xuguang Li, M. Parniak, 1993, Journal of medical virology.

Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1

M. Wainberg, R. Chandok, L. Kleiman, 1997, Journal of virology.

Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site

M. Wainberg, B. Roques, E. Arts, 1996, Journal of virology.

Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.

S. Sarafianos, L. Rohan, M. Parniak, 2014, International journal of pharmaceutics.

Biochemical Mechanism of HIV-1 Resistance to Rilpivirine*

M. Wainberg, S. Sarafianos, M. Parniak, 2012, The Journal of Biological Chemistry.

Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor.

M. Wainberg, H. Salomón, M. Parniak, 2002, AIDS research and human retroviruses.

Physicochemical and biochemical properties of 2',5'-linked RNA and 2',5'-RNA:3',5'-RNA "hybrid" duplexes.

A. Noronha, M. Damha, M. Parniak, 1998, Biochemistry.

Virion Instability of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Mutated in the Protease Cleavage Site between RT p51 and the RT RNase H Domain

M. Parniak, M. Abram, 2005, Journal of Virology.

Studies on the formation of N6-hydroxylysine in cell-free extracts of Aerobacter aerogenes 62-1.

M. Parniak, T. Viswanatha, G. Murray, 1979, Biochimica et biophysica acta.

Effect of metabolites on epsilon-N-hydroxylysine formation in cell-free extracts of Aerobacter aerogenes 62-1.

M. Parniak, T. Viswanatha, G. Murray, 1977, Canadian journal of biochemistry.

Quantitative determination of monosubstituted guanidines: a comparative study of different procedures.

M. Parniak, T. Viswanatha, G. Lange, 1983, Journal of biochemical and biophysical methods.

The Anti‐HIV Microbicide Candidate RC‐101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa

Phalguni Gupta, P. Marx, L. Rohan, 2013, American journal of reproductive immunology.

The K65R Mutation Confers Increased DNA Polymerase Processivity to HIV-1 Reverse Transcriptase*

M. Wainberg, M. Parniak, G. Borkow, 1996, The Journal of Biological Chemistry.

A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors

Michael A. Parniak, M. Parniak, Dimitrios Motakis, 2002, Antimicrobial Agents and Chemotherapy.

Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors

S. Sarafianos, E. Arnold, K. Das, 2014, Viruses.

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine

M. Wainberg, Q. Gao, M. Parniak, 1992, Journal of virology.

Expression, purification, and RNA-binding properties of HIV-1 p15gag nucleocapsid protein.

M. Wainberg, R. Geleziunas, L. Kleiman, 1993, Protein expression and purification.

Structural Basis of the Allosteric Inhibitor Interaction on the HIV‐1 Reverse Transcriptase RNase H Domain

R. Ishima, M. Parniak, Jinwoo Ahn, 2012, Chemical biology & drug design.

Interaction of HIV‐1 Reverse Transcriptase Ribonuclease H with an Acylhydrazone Inhibitor

Q. Gong, R. Ishima, M. Parniak, 2011, Chemical biology & drug design.

The activation of rat liver phenylalanine hydroxylase by limited proteolysis, lysolecithin, and tocopherol phosphate. Changes in conformation and catalytic properties.

J. Abita, S. Kaufman, M. Parniak, 1984, The Journal of biological chemistry.

Spectroscopic investigation of ligand interaction with hepatic phenylalanine hydroxylase: evidence for a conformational change associated with activation.

S. Kaufman, R. Phillips, M. Parniak, 1984, Biochemistry.

Identification of Alternative Binding Sites for Inhibitors of HIV-1 Ribonuclease H Through Comparative Analysis of Virtual Enrichment Studies

Anthony K. Felts, Krystal LaBarge, Joseph D. Bauman, 2011, J. Chem. Inf. Model..

Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase

N. Sluis-Cremer, M. Parniak, D. Arion, 2002, The Journal of Biological Chemistry.

Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase

Marc C. Johnson, D. H. Burke, V. Pathak, 2011, Nucleic acids research.

Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.

M A Wainberg, M. Wainberg, B. Brenner, 1994, Leukemia.

Conformational Changes in HIV-1 Reverse Transcriptase that Facilitate Its Maturation.

S. Sarafianos, G. Kawai, R. Ishima, 2019, Structure.

The p66 immature precursor of HIV‐1 reverse transcriptase

A. Gronenborn, N. G. Sharaf, R. Ishima, 2014, Proteins.

Synthesis of Boranoate, Selenoate, and Thioate Analogs of AZTp(4)A and Ap(4)A.

Roger A. Jones, S. Sarafianos, B. Gaffney, 2009, Tetrahedron.

Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission

S. Sarafianos, Yuan-Ping Shi, Minlu Hu, 2015, Pharmaceutical Research.

Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides.

C. Wilds, E. Nagy, C. Lok, 2002, Biochemistry.

Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.

M. Wainberg, B. Brenner, D. Moisi, 2002, Antiviral research.

Hybrids of RNA and Arabinonucleic Acids (ANA and 2‘F-ANA) Are Substrates of Ribonuclease H J. Am. Chem. Soc. 1998, 120, 12976−12977

I. Brukner, A. Noronha, C. Wilds, 1998 .

Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana.

M. Wainberg, B. Brenner, D. Moisi, 2002, Antiviral therapy.

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes

S. Sarafianos, M. Parniak, Maria E. Cilento, 2023, bioRxiv.

Variable tRNA content in HIV-1IIIB.

M. Wainberg, J. Mak, L. Kleiman, 1992, Biochemical and biophysical research communications.

Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase.

H. Mitsuya, M. Parniak, V. Prasad, 2000, The Journal of biological chemistry.

Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT

M. Wainberg, B. Brenner, D. Moisi, 2002, Antimicrobial Agents and Chemotherapy.

Interaction with a monoclonal antibody alters the expression of co-operativity by phenylalanine hydroxylase from rat liver.

R. Cotton, I. Jennings, M. Parniak, 1989, The Biochemical journal.

Incorporation of tRNA into normal and mutant HIV-1.

M. Wainberg, L. Kleiman, M. Parniak, 1991, Biochemical and biophysical research communications.

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA

Andrew D. Huber, S. Sarafianos, H. Mitsuya, 2013, Retrovirology.

Inhibitors of HIV-1 reverse transcriptase.

M. Parniak, Tatiana V. Ilina, 2008, Advances in pharmacology.

Enhancement of glycogen concentrations in primary cultures of rat hepatocytes exposed to glucose and fructose.

M. Parniak, N. Kalant, Lady, 1988, Biochemical Journal.

HIV-1 reverse transcriptase shows no specificity for the binding of primer tRNA(Lys3).

M. Wainberg, M. Parniak, D. Arion, 1996, Biochemical and biophysical research communications.

Anti-HIV-1 microbicide potential of the tight-binding nonnucleoside reverse transcriptase inhibitor UC781

M. Parniak, G. Borkow, R. Ben-Ari, 2001 .

First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G.

N. Krogan, C. Schiffer, M. Carpenter, 2012, ACS chemical biology.

Studies on the primary structure of rat liver phenylalanine hydroxylase.

S. Kaufman, M. Parniak, M. Iwaki, 1985, Biochemical and biophysical research communications.

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase

M. Parniak, Gadi Borkow, M. A. Wainberg, 1997, Journal of virology.

The Safety, Persistence, and Acceptability of an Antiretroviral Microbicide Candidate UC781

L. Meyn, K. Bunge, S. Hillier, 2012, Journal of acquired immune deficiency syndromes.

Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNase H domain of HIV-1 reverse transcriptase and structure-activity analysis of inhibitor analogs.

E. Arnold, W. Ho, M. Parniak, 2014, Journal of molecular biology.